Artificial Intelligence, Virtual Participants, and the Evolving FDA Regulatory Landscape

Artificial intelligence is moving faster than the rules designed to govern it, creating both opportunity and uncertainty for life sciences organizations. Regulators across the U.S., EU, and other global markets are taking different approaches to oversight, with requirements evolving around data privacy, algorithm transparency, risk management, and accountability. Understanding how frameworks such as the EU AI Act intersect with existing regulations is becoming critical for teams developing, deploying, or validating AI-driven solutions.

This overview clarifies how regulatory expectations are forming, where guidance remains fragmented, and what compliance leaders should be monitoring now to avoid downstream risk. It also highlights practical considerations for aligning AI innovation with regulatory readiness, from documentation practices to cross-functional governance.

Read the full piece to gain a clearer view of how emerging AI regulations may shape strategy, investment, and operational decision-making.